Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Myelodysplastic Syndromes 4 Lymphoma, Non-Hodgkin 4 Leukemia, Myelomonocytic, Juvenile 4 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4 Hemoglobinuria, Paroxysmal 4 Neoplasms 2 Melanoma 2 Leukemia 2 Hodgkin Disease 2 Squamous Non-Small Cell Lung Cancer 1 Squamous Cell Carcinoma of Head and Neck 1 Neuroblastoma 1 Lymphoma 1 Liver Neoplasms 1 Histiocytosis 1 Hemoglobinuria 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

Trastuzumab 350 Paclitaxel 334 Cyclophosphamide 315 Docetaxel 291 Capecitabine 181 Doxorubicin 180 Letrozole 165 Tamoxifen 145 Bevacizumab 124 Fulvestrant 118 Carboplatin 118 exemestane 111 Lapatinib 111 Anastrozole 111 Radiotherapy 105 Epirubicin 104 Gemcitabine 97 palbociclib 83 Exercise 78 Vinorelbine 77 Fluorouracil 77 Surveys and Questionnaires 71 pertuzumab 67 Filgrastim 64 Albumin-Bound Paclitaxel 64 eribulin 55 Magnetic Resonance Spectroscopy 55 Everolimus 52 Blood Specimen Collection 51 Zoledronic Acid 50

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Breast Neoplasms × Antibodies × Clear all

NCT03280563 2025-11-10

MORPHEUS HR+BC

Hoffmann-La Roche

Phase 1/2 Completed

144 enrolled 25 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡